Cargando…

Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19

In patients with non-alcoholic fatty liver disease (NAFLD) with or without type 2 diabetes mellitus (T2DM), alpha-2 macroglobulin (A2M), apolipoprotein A1 (ApoA1), and haptoglobin are associated with the risk of liver fibrosis, inflammation (NASH), and COVID-19. We assessed if these associations wer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deckmyn, Olivier, Poynard, Thierry, Bedossa, Pierre, Paradis, Valérie, Peta, Valentina, Pais, Raluca, Ratziu, Vlad, Thabut, Dominique, Brzustowski, Angelique, Gautier, Jean-François, Cacoub, Patrice, Valla, Dominique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945355/ https://www.ncbi.nlm.nih.gov/pubmed/35327501 http://dx.doi.org/10.3390/biomedicines10030699

Ejemplares similares

Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia
por: Poynard, Thierry, et al.
Publicado: (2023)

Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes
por: Poynard, Thierry, et al.
Publicado: (2019)

Hirsch Index and Truth Survival in Clinical Research
por: Poynard, Thierry, et al.
Publicado: (2010)

Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery
por: Peta, Valentina, et al.
Publicado: (2017)

Performance of serum apolipoprotein-A1 as a sentinel of Covid-19
por: Poynard, Thierry, et al.
Publicado: (2020)

Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B
por: Poynard, Thierry, et al.
Publicado: (2011)

Long‐term prognostic value of the FibroTest in patients with non‐alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease
por: Munteanu, Mona, et al.
Publicado: (2018)

Prospective external validation of a new non‐invasive test for the diagnosis of non‐alcoholic steatohepatitis in patients with type 2 diabetes
por: Poynard, Thierry, et al.
Publicado: (2021)

Impact of steatosis and inflammation definitions on the performance of NASH tests
por: Poynard, Thierry, et al.
Publicado: (2018)

The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis
por: Poynard, Thierry, et al.
Publicado: (2019)

External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV
por: Poynard, Thierry, et al.
Publicado: (2021)

Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease
por: Nascimbeni, Fabio, et al.
Publicado: (2016)

A new NRF2 activator for the treatment of human metabolic dysfunction-associated fatty liver disease
por: Hammoutene, Adel, et al.
Publicado: (2023)

Meta-analyses of FibroTest diagnostic value in chronic liver disease
por: Poynard, Thierry, et al.
Publicado: (2007)

Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison
por: Poynard, Thierry, et al.
Publicado: (2016)

LCR1 and LCR2, two multi‐analyte blood tests to assess liver cancer risk in patients without or with cirrhosis
por: Poynard, Thierry, et al.
Publicado: (2018)

Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis
por: Rudler, Marika, et al.
Publicado: (2015)

Assessment of Liver Fibrosis: Noninvasive Means
por: Poynard, Thierry, et al.
Publicado: (2008)

Validation of the Performance of A1HPV6, a Triage Blood Test for the Early Diagnosis and Prognosis of SARS-CoV-2 Infection
por: Maisonnasse, Pauline, et al.
Publicado: (2022)

Concordance in a World without a Gold Standard: A New Non-Invasive Methodology for Improving Accuracy of Fibrosis Markers
por: Poynard, Thierry, et al.
Publicado: (2008)

Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C
por: Poynard, Thierry, et al.
Publicado: (2004)

Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest)
por: Munteanu, Mona, et al.
Publicado: (2004)

Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity
por: Poynard, Thierry, et al.
Publicado: (2015)

The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis
por: Poynard, Thierry, et al.
Publicado: (2005)

Neurocognitive impairment in obesity and liver disease—An unsolved mystery
por: Kheloufi, Lyes, et al.
Publicado: (2023)

An Accurate Definition of the Status of Inactive Hepatitis B Virus Carrier by a Combination of Biomarkers (FibroTest-ActiTest) and Viral Load
por: Ngo, Yen, et al.
Publicado: (2008)

Correction: An Accurate Definition of the Status of Inactive Hepatitis B Virus Carrier by a Combination of Biomarkers (FibroTest-ActiTest) and Viral Load
por: Ngo, Yen, et al.
Publicado: (2008)

Successful rescue therapy with tenofovir in a patient with hepatic decompensation and adefovir resistant HBV mutant
por: Ratziu, Vlad, et al.
Publicado: (2006)

Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age
por: Poynard, Thierry, et al.
Publicado: (2011)

Significant gene expression differences in histologically “Normal” liver biopsies: Implications for control tissue
por: Asselah, Tarik, et al.
Publicado: (2008)

Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease
por: Ratziu, Vlad, et al.
Publicado: (2006)

Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease
por: Poynard, Thierry, et al.
Publicado: (2006)

Differential Levels of Alpha-2-Macroglobulin, Haptoglobin and Sero-Transferrin as Adjunct Markers for TB Diagnosis and Disease Progression in the Malnourished Tribal Population of Melghat, India
por: Bapat, Prachi R., et al.
Publicado: (2015)

Increased Prothrombin, Apolipoprotein A-IV, and Haptoglobin in the Cerebrospinal Fluid of Patients with Huntington's Disease
por: Huang, Yen-Chu, et al.
Publicado: (2011)

Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference
por: Munteanu, M., et al.
Publicado: (2016)

Performance of Biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in Patients with Severe Obesity: Meta Analysis of Individual Patient Data
por: Poynard, Thierry, et al.
Publicado: (2012)

Impact of Sarcopenia on the Severity of the Liver Damage in Patients With Non-alcoholic Fatty Liver Disease
por: Zambon Azevedo, Vittoria, et al.
Publicado: (2022)

Novel biomarkers predict liver fibrosis in hepatitis C patients: alpha 2 macroglobulin, vitamin D binding protein and apolipoprotein AI
por: Ho, Ai-Sheng, et al.
Publicado: (2010)

Haptoglobin increases with age in rat hippocampus and modulates Apolipoprotein E mediated cholesterol trafficking in neuroblastoma cell lines
por: Spagnuolo, Maria Stefania, et al.
Publicado: (2014)

Unique Contribution of Haptoglobin and Haptoglobin Genotype in Aneurysmal Subarachnoid Hemorrhage
por: Blackburn, Spiros L., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_rdfc8cp6fctq9mvrac3k6b4dra